Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
ME
Horizon Kinetics Medical ETF
MEDX
Volume
57
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
ME
MEDX
ME
Horizon Kinetics Medical ETF
MEDX
News
·
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
AUM
N/A
Volume
57
Yield
1.13%
Chart
Earnings
News
About
Dividends
Insider
Filings
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Zacks Investment Research · Jun 19, 2024
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Zacks Investment Research · May 1, 2024
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
Zacks Investment Research · Feb 7, 2024
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
Zacks Investment Research · Nov 3, 2023
Eli Lilly Soars on Blockbuster Q2 Earnings: ETFs to Tap
Eli Lilly (LLY) experienced its most significant surge in stock prices in over two decades following the release of an impressive second-quarter 2023 earnings report and an optimistic outlook. ETFs having the largest exposure to the drug maker could be compelling picks to tap the strong growth.
Zacks Investment Research · Aug 9, 2023
Biotech ETFs in Focus on Covid Vaccines' Fall Rollout
The FDA advised to Pfizer, Moderna and Novavax to manufacture single-strain jabs targeting the omicron subvariant XBB.1.5 should prove to be a victory for some biotech ETFs.
Zacks Investment Research · Jun 22, 2023
ETFs to Capitalize on Eli Lilly's Buyout of DICE Therapeutics
Eli Lilly (LLY) has agreed to acquire DICE Therapeutics (DICE) in a cash deal worth approximately $2.4 billion. This strategic move is part of Eli Lilly's efforts to bolster its immunology pipeline, specifically targeting immune disease-related treatments.
Zacks Investment Research · Jun 21, 2023
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
ME
MEDX
Horizon Kinetics Medical ETF
Buy
Sell
Market
Limit
Soon
MEDX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any MEDX yet.
Related Tickers
Earnings
Dividends
Last · Dec 23
Annual
Amount
$0.41
Yield
1.13%
Annual
$0.41